Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 1591 to 1600 of 2581 total matches.

Doxepin Cream for Pruritus

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 1994  (Issue 934)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The US Food and Drug Administration has approved the marketing of 5% doxepin hydrochloride cream (Zonalon - GenDerm) for treatment of pruritus due to eczematous dermatoses. Oral doxepin is used as a tricyclic antidepressant (Sinequan, and others).
Med Lett Drugs Ther. 1994 Oct 28;36(934):99-100 |  Show IntroductionHide Introduction

Safety of Calcium-Channel Blockers

   
The Medical Letter on Drugs and Therapeutics • Feb 14, 1997  (Issue 994)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Reports of increased mortality associated with calcium-channel blockers have caused concerns among patients taking these drugs and their physicians.
Med Lett Drugs Ther. 1997 Feb 14;39(994):13-4 |  Show IntroductionHide Introduction

Rituximab for Non-Hodgkins Lymphoma

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 1998  (Issue 1029)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Rituximab (Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas.
Med Lett Drugs Ther. 1998 Jun 19;40(1029):65-6 |  Show IntroductionHide Introduction

Mometasone Furoate Nasal Spray for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Feb 12, 1999  (Issue 1046)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
An intranasal spray formulation of the topical corticosteroid mometasone furoate, marketed for treatment of seasonal and perennial allergic rhinitis, has been advertised on television directly to the public.
Med Lett Drugs Ther. 1999 Feb 12;41(1046):16-7 |  Show IntroductionHide Introduction

Cool.click: A Needle-free Device For Growth Hormone Delivery

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001  (Issue 1095)
The Medical Letter  On Drugs and Therapeutics Published by The Medical Letter, Inc. • 1000 Main ...
A new needle-free system (cool.click) has been approved by the FDA for subcutaneous delivery of Saizen (recombinant somatotropin - Serono). Somatotropin is used for long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone. Children with growth hormone deficiency require injections daily or several times weekly for many years.
Med Lett Drugs Ther. 2001 Jan 8;43(1095):2-3 |  Show IntroductionHide Introduction

Newer Antihistamines

   
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001  (Issue 1103)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
With the coming of spring, direct-to-consumer (DTC) advertisements in newspapers, in magazines and on television are urging people with seasonal allergies to ask their doctors about one or another of the newer, non-sedating antihistamines.
Med Lett Drugs Ther. 2001 Apr 30;43(1103):35 |  Show IntroductionHide Introduction

Anakinra (Kineret) For Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 18, 2002  (Issue 1124)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Anakinra (Kineret - Amgen), an interleuken-1 (IL-1) receptor antagonist, has been approved by the FDA for treatment of moderately to severly active rheumatoid arthritis in adults who have failed at least one disease-modifying anti-rheumatic drug(DMARD) such as methotrexate (Medical Letter 2000; 24:57).
Med Lett Drugs Ther. 2002 Feb 18;44(1124):18-9 |  Show IntroductionHide Introduction

Amlodipine/Atorvastatin (Caduet)

   
The Medical Letter on Drugs and Therapeutics • Jul 05, 2004  (Issue 1186)
separately. The Medical Letter ® On Drugs and Therapeutics www.medicalletter.org Published ...
Caduet (Pfizer), a combination of the calcium-channel blocker amlodipine (Norvasc - Pfizer) and the HMG-CoA reductase inhibitor (statin) atorvastatin (Lipitor - Pfizer), is now available in the US. It was approved by the FDA for use in patients with indications for treatment with both amlodipine, which is used to treat hypertension and/or angina pectoris, and atorvastatin, which is used to treat dyslipidemia. The combination is bioequivalent to the 2 components taken separately.
Med Lett Drugs Ther. 2004 Jul 5;46(1186):56 |  Show IntroductionHide Introduction

Fentanyl Nasal Spray (Lazanda) for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
Letter® On Drugs and Therapeutics Volume 53 (Issue 1379/1380) December 12/26, 2011 ...
The FDA has approved a nasal spray formulation of fentanyl (Lazanda – Archimedes) for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to opioid therapy. Fentanyl is already available in the US for intravenous, intrathecal, epidural, transdermal and oral transmucosal use.
Med Lett Drugs Ther. 2011 Dec 12;53(1379):99-100 |  Show IntroductionHide Introduction

Tobramycin Inhalation Powder (Tobi Podhaler) for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2013  (Issue 1419)
The Medical Letter® On Drugs and Therapeutics Volume 55 (Issue 1419) June 24, 2013 Published ...
Inhaled antibiotics, which can achieve high concentrations in the lung with minimal systemic side effects, are probably the most effective therapy available for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. An orally inhaled dry powder formulation of the aminoglycoside antibiotic tobramycin (Tobi Podhaler – Novartis) has been approved by the FDA for management of P. aeruginosa pulmonary infection in cystic fibrosis patients ≥6 years old. The new formulation is administered via a hand-held pocket-sized inhaler. Tobramycin is also available as an...
Med Lett Drugs Ther. 2013 Jun 24;55(1419):51-2 |  Show IntroductionHide Introduction